Hengah
2021-06-12
Hzhshshdn
Novavax says COVID-19 vaccine shows immune response against Beta virus variant
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":188544046,"tweetId":"188544046","gmtCreate":1623456700685,"gmtModify":1634033029403,"author":{"id":3554375720188871,"idStr":"3554375720188871","authorId":3554375720188871,"authorIdStr":"3554375720188871","name":"Hengah","avatar":"https://static.tigerbbs.com/17324a07b91e24f255a5d31c782be01d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hzhshshdn</p></body></html>","htmlText":"<html><head></head><body><p>Hzhshshdn</p></body></html>","text":"Hzhshshdn","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/188544046","repostId":2142202973,"repostType":4,"repost":{"id":"2142202973","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623447457,"share":"https://www.laohu8.com/m/news/2142202973?lang=&edition=full","pubTime":"2021-06-12 05:37","market":"us","language":"en","title":"Novavax says COVID-19 vaccine shows immune response against Beta virus variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2142202973","media":"Reuters","summary":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune respo","content":"<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax says COVID-19 vaccine shows immune response against Beta virus variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax says COVID-19 vaccine shows immune response against Beta virus variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 05:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142202973","content_text":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.\nThe vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.\nNovavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.\nThe company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.\nHowever, the response against the Beta variant was slightly less, Novavax said.\nThe European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.\nThe company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.\n(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)","news_type":1},"isVote":1,"tweetType":1,"viewCount":224,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/188544046"}
精彩评论